3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
91
Carcinoma, Non-Small-Cell Lung
84
Neoplasms
48
Carcinoma, Renal Cell
44
Neoplasm Metastasis
40
Carcinoma, Hepatocellular
36
Squamous Cell Carcinoma of Head and Neck
35
Colorectal Neoplasms
31
Pancreatic Neoplasms
24
Lung Neoplasms
20
Stomach Neoplasms
19
Head and Neck Neoplasms
18
Carcinoma, Transitional Cell
17
Hodgkin Disease
16
Breast Neoplasms
16
Small Cell Lung Carcinoma
15
Ovarian Neoplasms
14
Urinary Bladder Neoplasms
13
Recurrence
13
Advanced Cancer
13
Glioblastoma
12
Brain Neoplasms
12
Lymphoma
11
Kidney Neoplasms
11
Glioma
11
Prostatic Neoplasms
10
Lymphoma, Non-Hodgkin
10
Uveal Melanoma
9
Triple Negative Breast Neoplasms
9
Sarcoma
9
Interventions
Cyclophosphamide
44
Peripheral Blood Stem Cell Transplantation
25
fludarabine phosphate
24
Doxorubicin
23
Etoposide
22
Vincristine
21
Prednisone
20
Whole-Body Irradiation
19
Rituximab
18
Filgrastim
16
Brentuximab Vedotin
15
Mycophenolic Acid
14
Cyclosporine
14
Busulfan
14
Methotrexate
12
Radiotherapy
11
Cytarabine
11
Carboplatin
10
Melphalan
9
Ifosfamide
9
Antilymphocyte Serum
9
Tacrolimus
8
Methylprednisolone
8
Gemcitabine
8
Bortezomib
8
Dexamethasone
7
Vorinostat
6
Everolimus
6
Crizotinib
6
romidepsin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large-Cell, Anaplastic
×
Nivolumab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled